Burcu Tunakan: Turning Collaboration into Better Outcomes for People with Hemophilia
Burcu Tunakan, Vice President of US Hematology and Endocrinology Franchise Lead at Pfizer, shared a post on LinkedIn:
“Today, we were thrilled to host our second Hemophilia Day at Pfizer Headquarters.
Leading Hematologists across the nation joined us for a day of candid dialogue and collaboration, at a time when the science in this space is advancing faster than ever.
We exchanged perspectives and insights which will shape our team’s actions to advance care for people living with Hemophilia.
Because there is still meaningful work ahead.
And our team is fully committed to turning breakthrough innovation into real, lasting patient impact, by listening deeply and working alongside this community every step of the way.
Thank you to every leading expert who joined us.
Your partnership makes the difference.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines